Abstract: Various aspects of the subject technology relate to systems, methods, and machine-readable media for bridging native tokens. Various aspects may include initializing a first blockchain by allocating a plurality of native tokens. Aspects may also include transferring, using a bridge, one or more transactions from a second blockchain to the first blockchain using locked tokens on the second blockchain as collateral. Aspects may also include minting new native tokens at the first blockchain when a value of transactions sum to the plurality of native tokens and the plurality of native tokens are backed by the locked tokens. Aspects may also include reporting, to the second blockchain, the amount of tokens used for the transaction fees in the one or more transactions. Aspects may also include burning, at the second blockchain, tokens corresponding to the amount of tokens used for paying transaction fees.

Abstract: Various aspects of the subject technology relate to systems, methods, and machine-readable media for bridging native tokens. Various aspects may include initializing a first blockchain by allocating a plurality of native tokens. Aspects may also include transferring, using a bridge, one or more transactions from a second blockchain to the first blockchain using locked tokens on the second blockchain as collateral. Aspects may also include minting new native tokens at the first blockchain when a value of transactions sum to the plurality of native tokens and the plurality of native tokens are backed by the locked tokens. Aspects may also include reporting, to the second blockchain, the amount of tokens used for the transaction fees in the one or more transactions. Aspects may also include burning, at the second blockchain, tokens corresponding to the amount of tokens used for paying transaction fees.

Abstract: The disclosure provides a method of producing a pharmaceutical composition. The method comprises (a) dissolving an active pharmaceutical ingredient (API) in a liquid vehicle to form a liquid medicament; (b) contacting the liquid medicament with a pharmaceutical carrier; (c) contacting the composition comprising the liquid medicament and pharmaceutical carrier with a pharmaceutical coating material to form a liqui-mass composition; and (d) pelletising the liqui-mass composition to form the pharmaceutical composition.

Abstract: The disclosure provides a method of producing a pharmaceutical composition. The method comprises (a) dissolving an active pharmaceutical ingredient (API) in a liquid vehicle to form a liquid medicament; (b) contacting the liquid medicament with a pharmaceutical carrier; (c) contacting the composition comprising the liquid medicament and pharmaceutical carrier with a pharmaceutical coating material to form a liqui-mass composition; and (d) pelletising the liqui-mass composition to form the pharmaceutical composition.

Abstract: This invention relates generally to a garage door control system. A system includes, but is not limited to: sensor devices that detect a position of a garage door from a floor using a distance from the devices and the door, the devices being mounted at a far end of a horizontal guidance track; a control unit coupled to the sensor devices, the control unit including at least a computer processor; a power distribution and control relay unit; a wireless communication interface operable to communicate wirelessly; and a link connected to the garage door motor; and a user interface unit in place of the existing garage door button, wherein the user interface receives power from the power distribution and control relay unit via wires repurposed from control signal wires of the existing garage door button, the user interface including: a wireless communication interface to communicate wirelessly; and a display screen.